leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...7891011121314151617...235236»
  • ||||||||||  Journal, Combination therapy, Metastases:  Early tumor shrinkage as a prognostic predictor in chemotherapy-na (Pubmed Central) -  Sep 7, 2024   
    Oral folinic acid supplementation is effective and safe in improving ASD symptoms, with more pronounced benefits in children with high titers of folate receptor autoantibodies. ETS may be a prognostic predictor in chemotherapy-na
  • ||||||||||  fosifloxuridine nafalbenamide (NUC-3373) / NuCana
    Trial completion date, Trial termination, Combination therapy, Metastases:  NuTide:323: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (clinicaltrials.gov) -  Sep 2, 2024   
    P2,  N=182, Terminated, 
    Trial completion date: Mar 2025 --> Aug 2024 | Active, not recruiting --> Terminated; A pre-planned initial analysis concluded that the study was unlikely to achieve its primary objective of demonstrating superior progression-free survival. Based on the Steering Committee's recommendation, the Sponsor has closed the study.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  Duodenal adenocarcinoma at stage IV: A critical look at diagnostic pathways and treatment modalities. (Pubmed Central) -  Sep 2, 2024   
    Molecular profiling was crucial in guiding treatment decisions, although MSI, HER2, and PD-1 were negative, and the tumor showed no mismatch repair protein deficiency. This article emphasizes the importance of early integration of palliative care and the value of comprehensive pathological analysis in managing advanced duodenal adenocarcinoma, providing insights into diagnostic and therapeutic strategies for this complex case.
  • ||||||||||  Retrospective data, Journal:  Pancreatic Cancer: A Retrospective Study From the Najran Region of Saudi Arabia. (Pubmed Central) -  Sep 1, 2024   
    Additionally, FOLFIRINOX as a first-line treatment showed better survival rates than gemcitabine alone. Raising awareness among healthcare providers on the alarming signs of pancreatic cancer and the introduction of personalized oncology might improve the outcome of this fatal malignancy.
  • ||||||||||  ALL in Pregnancy With Challenging Conditions & Side Effects (LEVEL 3, HALL B3) -  Aug 30, 2024 - Abstract #SOHO2024SOHO_363;    
    Maintenance Phase: 6-Mercaptopurine (6-MP) The Maintenance Phase interrupted many times because of pancytopenia and hepatotoxicity as an adverse reaction related to (6-MP), so dose was reduced first from 75% then to 50%...Her son, now 8 years old, is doing well, her cardiac function EF 55%. This case is considered uncommon and rare due to the multiple adverse drug reactions; The patient's journey highlights the complexity and challenges of managing All in a pregnant patient.
  • ||||||||||  Trial completion, Trial completion date, Adverse events, Combination therapy, Metastases:  Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) -  Aug 28, 2024   
    P2,  N=70, Completed, 
    This case is considered uncommon and rare due to the multiple adverse drug reactions; The patient's journey highlights the complexity and challenges of managing All in a pregnant patient. Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Mar 2024
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    A CASE OF METASTATIC CARCINOMA LYMPHADENOPATHY MASQUERADE AS A TUBERCULOUS LYMPHADENITIS () -  Aug 27, 2024 - Abstract #MTS2024MTS_261;    
    After the third cycle, lymph nodes regressed to 2 x 1 cm, demonstrating a positive response to chemotherapy and anti-tuberculous treatment. Discussion The challenge of diagnosing chronic granulomatous inflammation in lymphadenopathy, especially when it responds poorly to anti-tuberculous therapy, necessitates exploring alternative diagnoses.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases:  Efficacy of immune checkpoint inhibitors combined with bevacizumab in MSS/pMMR advanced colorectal cancer after first-line treatment failure. (Pubmed Central) -  Aug 27, 2024   
    The experimental group consisted of 60 patients treated with the Sintilimab combined with Bevacizumab regimen...Patients aged ?60 years, male patients, and those in the experimental group showed better treatment responses in this study. By administering immune checkpoint inhibitors in combination with bevacizumab to patients with advanced colorectal cancer with MSS/pMMR disease for whom first-line treatment failed, not only did the patients' prognosis improve, but the adverse drug reactions were also safe and controllable.
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Journal, BRCA Biomarker, PARP Biomarker:  Germline BRCA1-Mutated Synchronous and Metachronous Pancreatic Acinar Cell Carcinoma With Long-Term Survival. (Pubmed Central) -  Aug 27, 2024   
    Considering that PACC is likely to have BRCA1/2 mutations responsible for HBOC, we need to be aware of the possible presence of multifocal and/or metachronous tumors in patients with PACC. Additionally, patients with PACC should undergo genetic examinations, which would be beneficial in determining treatment strategies and health care for blood relatives.
  • ||||||||||  Phase classification, Enrollment change, Trial termination:  QUILT-3.080: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) -  Aug 27, 2024   
    P1/2,  N=3, Terminated, 
    Not yet recruiting --> Recruiting | Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2024 Phase classification: P1b/2 --> P1/2 | N=173 --> 3 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal, Metastases:  Nanoparticle Polymeric Micellar Paclitaxel Versus Paclitaxel for Patients with Advanced Gastric Cancer. (Pubmed Central) -  Aug 26, 2024   
    The follow-up data from our prospective non-randomized controlled study revealed a considerable survival advantage in DFS offered by adjuvant chemotherapy with UFT/LV administered for six months over surgery alone in individuals with high-risk stage II CC. NPMP combined chemotherapy offers a new, active, and safe treatment for patients with AGC.
  • ||||||||||  Trial primary completion date:  Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma (clinicaltrials.gov) -  Aug 26, 2024   
    P1,  N=20, Active, not recruiting, 
    NPMP combined chemotherapy offers a new, active, and safe treatment for patients with AGC. Trial primary completion date: Oct 2024 --> Oct 2023
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Effect of lidocaine pumped through hepatic artery to relieve pain of hepatic artery infusion chemotherapy. (Pubmed Central) -  Aug 22, 2024   
    Both groups received oxaliplatin (OXA) based FOLFOX protocol via electronic infusion pump...At each point of time from Time point 01 through Time point 04, the mean VAS scores in the study group were smaller and GCQ scores were higher than those in the control group, and the differences were both statistically significant (P?<?0.05). Lidocaine infusion through the hepatic artery during HAIC effectively reduces intraoperative and postoperative pain and improves patient satisfaction with pain management, making it a valuable technique for clinical practice.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment closed, Trial completion date, Trial primary completion date, Head-to-Head, Surgery:  CAIRO6: Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (clinicaltrials.gov) -  Aug 22, 2024   
    P2/3,  N=358, Active, not recruiting, 
    Lidocaine infusion through the hepatic artery during HAIC effectively reduces intraoperative and postoperative pain and improves patient satisfaction with pain management, making it a valuable technique for clinical practice. Recruiting --> Active, not recruiting | Trial completion date: Aug 2026 --> Jun 2029 | Trial primary completion date: Aug 2024 --> Dec 2025
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    New trial:  Stratification for F-L Therapy After LT (clinicaltrials.gov) -  Aug 21, 2024   
    P=N/A,  N=1, Completed, 
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene
    Journal:  Trametinib potentiates anti-PD-1 efficacy in tumors established from chemotherapy-primed pancreatic cancer cells. (Pubmed Central) -  Aug 20, 2024   
    As the combinations of chemotherapy, including the FOLFIRINOX (5-fluorouracil (5FU), irinotecan, and oxaliplatin) regimen, and ICIs have failed to demonstrate clinical benefit in patients with metastatic PDAC tumors, there is increasing interest in identifying therapeutic approaches to potentiate ICI efficacy in PDAC patients...Furthermore, we found that the MEK inhibitor Trametinib enables additional infiltration of highly functional CD8+ T cells into the KPC-FIO tumors and potentiates the efficacy of anti-PD-1 antibody in syngeneic mouse models. Our findings provide a rationale for combining Trametinib and anti-PD-1 antibodies in PDAC patients following neoadjuvant or short-term FOLFIRINOX treatment to achieve effective anti-tumor responses.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Eosinophilic Gastritis Associated With Gastric Adenocarcinoma Presenting With Massive Gastric Outlet Obstruction (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_5584;    
    This case highlights the importance of keeping malignancy on the differential diagnosis in the setting of gastric outlet obstruction with evidence of eosinophilic gastritis. Figure: Coronal CT with diffuse proximal distension of the stomach, right upper quadrant malrotation, wall thickening of gastroduodenal junction.
  • ||||||||||  Opdivo (nivolumab) / BMS
    A Surprising Case of Gastric Adenocarcinoma Metastatic to Skeletal Muscle (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_5569;    
    Case Description/ A 69-year-old male with a history of alcohol abuse and recurrent gastric adenocarcinoma on palliative FOLFOX and nivolumab presented for 2 weeks of progressive right leg pain, weakness, rigidity, and edema...This case highlights the importance of a broad differential when evaluating localized symptoms in gastric cancer patients. Despite their rarity, skeletal muscle metastases must be considered.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Acute Terminal Ileitis Secondary to FOLFOX Therapy for Stage IIIC Cecal Adenocarcinoma (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_5468;    
    Introduction : FOLFOX is a combination of 5-fluorouracil (5-FU), oxaliplatin, and leucovorin used to treat gastric, bowel, pancreatic, breast, and head and neck carcinomas...After shared decision-making, the patient elected to continue FOLFOX therapy for 6 months for her aggressive, poorly differentiated cecal adenocarcinoma and start a prolonged prednisone taper...The treatment includes decreasing the dose or discontinuation of FOLFOX. A steroid taper can also be used to decrease inflammation and reduce the frequency of diarrhea.
  • ||||||||||  Tecentriq (atezolizumab) / Roche
    A Rare Case of High-Grade Neuroendocrine Carcinoma in the Setting of Barrett's Esophagus (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_4465;    
    He underwent treatment with Carboplatin/Etoposide/Atezolizumab (4 cycles) but experienced disease progression...Understanding the molecular mechanisms underlying the transformation of BE into NETs is crucial for developing treatments for this rare but aggressive histological subtype. Figure: Esophagogastroduodenoscopy (EDG) images showing multiple irregular shaped masses in the esophagus